Neuroprotective effects of riluzole in Alzheimer's disease: A comprehensive review
Fundamental & Clinical Pharmacology · 2024-04 · 38 (2) · 225-237
DOI: 10.1111/fcp.12955 ↗At a glance
Übersichtsarbeit in Fundamental & Clinical Pharmacology, published online on 2023-09-27. Written by Maryam Golmohammadi and 11 co-authors. Institution: School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Major MEDLINE topics: Neuroprotective Agents, Alzheimer Disease. Cited 33 times so far (Crossref); 132 references.
Topics: Demenz
Abstract (original language)
Background
Despite several hundred clinical trials of drugs that initially showed promise, there has been limited clinical improvement in Alzheimer's disease (AD). This may be attributed to the existence of at least 25 abnormal cellular pathways that underlie the disease. It is improbable for a single drug to address all or most of these pathways, thus even drugs that show promise when administered alone are unlikely to produce significant results. According to previous studies, eight drugs, namely, dantrolene, erythropoietin, lithium, memantine, minocycline, piracetam, riluzole, and silymarin, have been found to target multiple pathways that are involved in the development of AD. Among these drugs, riluzole is currently indicated for the treatment of medical conditions in both adult patients and children and has gained increased attention from scientists due to its potential in the excitotoxic hypothesis of neurodegenerative diseases.
Objective
The aim of this study was to investigate the effects of drugs on AD based on cellular and molecular mechanisms.
Methods
The literature search for this study utilized the Scopus, ScienceDirect, PubMed, and Google Scholar databases to identify relevant articles.
Results
Riluzole exerts its effects in AD through diverse pathways including the inhibition of voltage‐dependent sodium and calcium channels, blocking AMPA and NMDA receptors and inhibiting the release of glutamic acid release and stimulation of EAAT1‐EAAT2.
Conclusion
In this review article, we aimed to review the neuroprotective properties of riluzole, a glutamate modulator, in AD, which could benefit patients with the disease.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Polymer Engineering, Amirkabir University of Technology, Tehran, Iran.
- College of Pharmacy, Al-Bayan University, Baghdad, Iraq.
- Medical Surgical Nursing Department, King Khalid University, Khamis Mushate, Saudi Arabia.
- Department of General Studies, Universidad Continental, Lima, Peru.
- Department of Life Sciences and Biological Sciences, IES University, Bhopal, Madhya Pradesh, India.
ORCID profiles: Mohammad Yasin Zamanian
Cite
APA
Golmohammadi, M., Mahmoudian, M., Hasan, E. K., Alshahrani, S. H., Romero-Parra, R. M., Malviya, J., Hjazi, A., Najm, M. A. A., Almulla, A. F., Zamanian, M. Y., Kadkhodaei, M., & Mousavi, N. (2024). Neuroprotective effects of riluzole in Alzheimer's disease: A comprehensive review. Fundamental & Clinical Pharmacology, 38(2), 225-237. https://doi.org/10.1111/fcp.12955
Vancouver
Golmohammadi M, Mahmoudian M, Hasan EK, Alshahrani SH, Romero-Parra RM, Malviya J, et al. Neuroprotective effects of riluzole in Alzheimer's disease: A comprehensive review. Fundamental & Clinical Pharmacology. 2024;38(2):225-237. doi:10.1111/fcp.12955
BibTeX
@article{Golmohammadi2024,
author = {Golmohammadi, Maryam and Mahmoudian, Mohammadreza and Hasan, Ekhlas Khammas and Alshahrani, Shadia Hamoud and Romero-Parra, Rosario Mireya and Malviya, Jitendra and Hjazi, Ahmed and Najm, Mazin A A and Almulla, Abbas F and Zamanian, Mohammad Yasin and Kadkhodaei, Mona and Mousavi, Nazanin},
title = {Neuroprotective effects of riluzole in Alzheimer's disease: A comprehensive review},
journal = {Fundamental & Clinical Pharmacology},
year = {2024},
volume = {38},
number = {2},
pages = {225--237},
doi = {10.1111/fcp.12955}
}
EUVIMED